Igor Gonikhin

Partner at Biovision Ventures · Berlin, Germany

Invests in AI

Igor Gonikhin's investor profile lists AI alongside Healthcare & Biotech and Biotech & Pharma, at Series B. The record holds 8 deals, among them Botkin.AI, IAG, Image Analysis Group and Immusoft.

Email Investor

Email Investor

Credits to line up before a Series B round

Igor Gonikhin backs companies at Series B. A few of the larger credit programs on AI Perks for teams at that point:

Portfolio on record

Portfolio companies

  • Botkin.AI
  • IAG, Image Analysis Group
  • Immusoft
  • RBV Capital
  • RetroSense Therapeutics
  • Da Vinci Capital
  • Pipeline Therapeutics
  • Bonti

Investment focus

Backs startups in
Artificial Intelligence, Healthcare & Biotech, Biotech & Pharma
Rounds
Series B
Profile
Venture investor
Deals on record
8
Based in
Berlin, Germany

Ready to pitch AI investors?

AI Perks profiles show public professional information only, so there are no contact details here. Continue to find investors, send your pitch and track the replies.

Email Investor

Email Investor

More AI investors on AI Perks

Browse all AI investors

Questions founders ask

Does Igor Gonikhin invest in AI startups?
Yes. Artificial Intelligence is one of the sectors on Igor Gonikhin's investor profile, together with Healthcare & Biotech and Biotech & Pharma. The stages on record are Series B.
Which companies has Igor Gonikhin backed?
The record lists 8 deals, including Botkin.AI, IAG, Image Analysis Group, Immusoft, RBV Capital and RetroSense Therapeutics. None of them has a perk listed on AI Perks yet.
What credits can a startup claim before pitching Igor Gonikhin?
For a company raising a Series B round, AI Perks lists credits such as Atlassian (up to $30,000), Oracle GTM (up to $5,000), HighLevel (up to $12,000) and SendGrid/Twilio (up to $10,000), with each program's terms and how to apply.
Does AI Perks publish investor contact details?
No. AI Perks profiles show public professional information only: name, role, location, stages, sectors and the portfolio on record. To reach investors, continue with the Email Investor button below.Email Investor

Email Investor

Source: public professional information. Is this you? Request removal

Email Investor

Email Investor